ACS Chemical Biology,
Journal Year:
2023,
Volume and Issue:
18(2), P. 285 - 295
Published: Jan. 17, 2023
Here,
we
report
a
comprehensive
profiling
of
sulfur(VI)
fluorides
(SVI-Fs)
as
reactive
groups
for
chemical
biology
applications.
SVI-Fs
are
functionalities
that
modify
lysine,
tyrosine,
histidine,
and
serine
sidechains.
A
panel
were
studied
with
respect
to
hydrolytic
stability
reactivity
nucleophilic
amino
acid
The
use
covalently
carbonic
anhydrase
II
(CAII)
range
kinases
was
then
investigated.
Finally,
the
SVI-F
used
in
live
cell
chemoproteomic
workflows,
identifying
novel
protein
targets
based
on
type
used.
This
work
highlights
how
can
be
tool
expand
liganded
proteome.
Cell,
Journal Year:
2022,
Volume and Issue:
185(5), P. 916 - 938.e58
Published: Jan. 21, 2022
Treatment
of
severe
COVID-19
is
currently
limited
by
clinical
heterogeneity
and
incomplete
description
specific
immune
biomarkers.
We
present
here
a
comprehensive
multi-omic
blood
atlas
for
patients
with
varying
severity
in
an
integrated
comparison
influenza
sepsis
versus
healthy
volunteers.
identify
signatures
correlates
host
response.
Hallmarks
disease
involved
cells,
their
inflammatory
mediators
networks,
including
progenitor
cells
myeloid
lymphocyte
subsets,
features
the
repertoire,
acute
phase
response,
metabolism,
coagulation.
Persisting
activation
involving
AP-1/p38MAPK
was
feature
COVID-19.
The
plasma
proteome
enabled
sub-phenotyping
into
patient
clusters,
predictive
outcome.
Systems-based
integrative
analyses
tensor
matrix
decomposition
all
modalities
revealed
groupings
linked
specificity
compared
to
sepsis.
Our
approach
will
support
future
drug
development,
trial
design,
personalized
medicine
approaches
Frontiers in Immunology,
Journal Year:
2023,
Volume and Issue:
14
Published: Jan. 26, 2023
The
emergence
of
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
caused
a
pandemic
named
disease
2019
(COVID-19)
that
has
become
the
greatest
worldwide
public
health
threat
this
century.
Recent
studies
have
unraveled
numerous
mysteries
SARS-CoV-2
pathogenesis
and
thus
largely
improved
COVID-19
vaccines
therapeutic
strategies.
However,
important
questions
remain
regarding
its
therapy.
In
review,
recent
research
advances
on
mechanism
are
quickly
summarized.
We
mainly
discuss
current
therapy
strategies
for
COVID-19,
with
an
emphasis
antiviral
agents,
neutralizing
antibody
therapies,
Janus
kinase
inhibitors,
steroids.
When
necessary,
specific
mechanisms
history
present,
representative
described
in
detail.
Finally,
we
key
outstanding
future
directions
development
treatment.
Advanced Materials,
Journal Year:
2021,
Volume and Issue:
34(1)
Published: Oct. 8, 2021
Autoimmune
diseases
are
the
third
most
common
disease
influencing
quality
of
life
many
patients.
Here,
a
programmed
cell
death-ligand
1
+
(PD-L1)
mesenchymal
stem
(MSC)
derived
extracellular
vesicles
(MSC-sEVs-PD-L1)
using
lentivirus-mediated
gene
transfection
technology
is
developed
for
reconfiguration
local
immune
microenvironment
affected
tissue
in
autoimmune
diseases.
MSC-sEVs-PD-L1
exhibits
an
impressive
ability
to
regulate
various
activated
cells
immunosuppressed
state
vitro.
More
importantly,
dextran
sulfate
sodium-induced
ulcerative
colitis
(UC)
and
imiquimod-induced
psoriasis
mouse
models,
significantly
high
accumulation
observed
inflamed
tissues
compared
PD-L1+
MSCs.
Therapeutic
efficiency
both
UC
models
demonstrated
reshape
inflammatory
ecosystem
context.
A
as
natural
delivery
platform
treatment
with
clinical
potential.
Immune Network,
Journal Year:
2022,
Volume and Issue:
22(1)
Published: Jan. 1, 2022
In
the
past
few
decades,
biological
drugs
and
small
molecule
inhibitors
targeting
inflammatory
cytokines,
immune
cells,
intracellular
kinases
have
become
standard-of-care
to
treat
autoimmune
diseases.
Inhibition
of
TNF,
IL-6,
IL-17,
IL-23
has
revolutionized
treatment
diseases,
such
as
rheumatoid
arthritis,
ankylosing
spondylitis,
psoriasis.
B
cell
depletion
therapy
using
anti-CD20
mAbs
shown
promising
results
in
patients
with
neuroinflammatory
inhibition
survival
factors
is
approved
for
systemic
lupus
erythematosus.
Targeting
co-stimulatory
molecules
expressed
on
Ag-presenting
cells
T
also
expected
therapeutic
potential
diseases
by
modulating
function.
Recently,
kinase
JAK
family,
which
responsible
signal
transduction
from
multiple
receptors,
garnered
great
interest
field
hematologic
However,
there
are
still
unmet
medical
needs
terms
efficacy
safety
profiles.
Emerging
therapies
aim
induce
tolerance
without
compromising
function,
advanced
molecular
engineering
techniques.
